New hope for colorectal cancer: smarter drug timing may extend control
NCT ID NCT04587128
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This study tests a new way of using targeted drugs (panitumumab or cetuximab) to better control metastatic colorectal cancer that cannot be removed by surgery. About 34 people with left-sided tumors will receive these drugs early in their treatment, with the goal of keeping the disease from growing for as long as possible. Participants will be followed for up to 5 years to see how well the strategy works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.